120 related articles for article (PubMed ID: 36403175)
1. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas: "it's a numbers game"-implications for WNT medulloblastoma dose-reduction clinical trials.
Gottardo NG
Acta Neuropathol; 2023 Jan; 145(1):145-147. PubMed ID: 36403175
[No Abstract] [Full Text] [Related]
2. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.
Goschzik T; Mynarek M; Doerner E; Schenk A; Spier I; Warmuth-Metz M; Bison B; Obrecht D; Struve N; Kortmann RD; Schmid M; Aretz S; Rutkowski S; Pietsch T
Acta Neuropathol; 2022 Dec; 144(6):1143-1156. PubMed ID: 36181537
[TBL] [Abstract][Full Text] [Related]
3. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.
Adamson DC; Shi Q; Wortham M; Northcott PA; Di C; Duncan CG; Li J; McLendon RE; Bigner DD; Taylor MD; Yan H
Cancer Res; 2010 Jan; 70(1):181-91. PubMed ID: 20028867
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas.
Lindsey JC; Hill RM; Megahed H; Lusher ME; Schwalbe EC; Cole M; Hogg TL; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(12):e344-6; author reply e347-8. PubMed ID: 21357788
[No Abstract] [Full Text] [Related]
5. OTX1 and OTX2 Genes in Medulloblastoma.
Figueira Muoio VM; Uno M; Oba-Shinjo S; da Silva R; Araújo Pereira BJ; Clara C; Matushita H; Marie SNK
World Neurosurg; 2019 Jul; 127():e58-e64. PubMed ID: 30797919
[TBL] [Abstract][Full Text] [Related]
6. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
[TBL] [Abstract][Full Text] [Related]
7. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
8. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.
Boulay G; Awad ME; Riggi N; Archer TC; Iyer S; Boonseng WE; Rossetti NE; Naigles B; Rengarajan S; Volorio A; Kim JC; Mesirov JP; Tamayo P; Pomeroy SL; Aryee MJ; Rivera MN
Cancer Discov; 2017 Mar; 7(3):288-301. PubMed ID: 28213356
[TBL] [Abstract][Full Text] [Related]
9. Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.
Wortham M; Guo C; Zhang M; Song L; Lee BK; Iyer VR; Furey TS; Crawford GE; Yan H; He Y
PLoS One; 2014; 9(9):e107156. PubMed ID: 25198066
[TBL] [Abstract][Full Text] [Related]
10. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
11. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
12. p53 and Meduloblastoma.
Ramaswamy V; Nör C; Taylor MD
Cold Spring Harb Perspect Med; 2015 Dec; 6(2):a026278. PubMed ID: 26684332
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines.
Bunt J; de Haas TG; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
Mol Cancer Res; 2010 Oct; 8(10):1344-57. PubMed ID: 21047732
[TBL] [Abstract][Full Text] [Related]
14. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.
Bunt J; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
PLoS One; 2011; 6(10):e26058. PubMed ID: 22016811
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ
Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256
[TBL] [Abstract][Full Text] [Related]
16. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
17. Clinical and mutational profiles of adult medulloblastoma groups.
Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
[TBL] [Abstract][Full Text] [Related]
18. Isolated Bone Recurrence of Medulloblastoma With MYCN Amplification and TP53 Loss: A Case Report.
Takahashi Y; Kudo K; Ogawa K; Sato T; Kamio T; Sasaki S; Kobayashi A; Ito T; Yamamoto T; Asano K; Ohkuma H; Kurose A; Ito E; Terui K
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e593-e596. PubMed ID: 34133388
[TBL] [Abstract][Full Text] [Related]
19. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?
Mani S; Chatterjee A; Dasgupta A; Shirsat N; Epari S; Chinnaswamy G; Gupta T
Oncotarget; 2023 Feb; 14():105-110. PubMed ID: 36749287
[TBL] [Abstract][Full Text] [Related]
20. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.
de Haas T; Oussoren E; Grajkowska W; Perek-Polnik M; Popovic M; Zadravec-Zaletel L; Perera M; Corte G; Wirths O; van Sluis P; Pietsch T; Troost D; Baas F; Versteeg R; Kool M
J Neuropathol Exp Neurol; 2006 Feb; 65(2):176-86. PubMed ID: 16462208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
